TPD & Induced Proximity Summit Leaderboard
  • Tuesday, June 23, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 78

Author

Pharma Journalist 8887 posts 0 comments

Vividion and Bayer Advance Oncology Pipeline with Clinical-Stage WRN Inhibitor

Jun 6, 2025
Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured…
Read More...

Camurus and Lilly Partner on Long-Acting FluidCrystal Incretins

Jun 5, 2025
Camurus and Eli Lilly and Company have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, and…
Read More...

SpyGlass Pharma Raises $75M to Advance Glaucoma Drug Delivery Platform

Jun 4, 2025
SpyGlass Pharma, a privately held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide…
Read More...

EU Approves Roche’s Evrysdi as First Oral Treatment for SMA

Jun 4, 2025
Roche announced that the European Commission (EC) has approved a label extension for Evrysdi (risdiplam) to include a new, room-temperature stable tablet for people living with spinal…
Read More...

Agenus, Zydus Ink $141M Deal to Advance BOT/BAL, Expand U.S. Biologics Production

Jun 4, 2025
Agenus Inc. announced it has signed definitive partnership agreements with Zydus Lifesciences Ltd., including its subsidiaries/affiliates, hereafter referred to as “Zydus,” designed to…
Read More...

FDA Approves NUBEQA for Metastatic Prostate Cancer

Jun 4, 2025
Bayer announced that the U.S. Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor, NUBEQA (darolutamide), for the treatment of adult patients with…
Read More...

EU Approves ADCETRIS Combo for Newly Diagnosed Advanced Hodgkin Lymphoma

Jun 4, 2025
Takeda announced that the European Commission (EC) approved ADCETRIS (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone…
Read More...

Regeneron Boosts Obesity Pipeline with Dual GLP-1/GIP Agonist Deal

Jun 4, 2025
Regeneron Pharmaceuticals, Inc. announced a strategic in-licensing agreement with Hansoh Pharmaceuticals Group Company Limited (“Hansoh”) to acquire exclusive clinical development and…
Read More...

Honoring Excellence: The 10th Annual Microbiome Movement Awards

Jun 3, 2025
As part of the 10th anniversary celebrations, the 2025 Microbiome Movement Summit will host the Microbiome Movement Awards ceremony—a new special feature for the 10th annual summit.…
Read More...

Moderna’s mNEXSPIKE COVID-19 Vaccine Wins FDA Approval

Jun 3, 2025
Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved mNEXSPIKE (mRNA-1283), a new vaccine against COVID-19, for use in all adults 65 and older, as well…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.